Cargando…

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor

Cell plasma membrane proteins are considered as gatekeepers of the cell and play a major role in regulating various processes. Transport proteins constitute a subclass of cell plasma membrane proteins enabling the exchange of molecules and ions between the extracellular environment and the cytosol....

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Campenhout, Raf, Muyldermans, Serge, Vinken, Mathieu, Devoogdt, Nick, De Groof, Timo W.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825061/ https://www.ncbi.nlm.nih.gov/pubmed/33418902 http://dx.doi.org/10.3390/biom11010063

Ejemplares similares

Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury
por: Van Campenhout, Raf, et al.
Publicado: (2023)

Mechanisms Underlying Connexin Hemichannel Activation in Disease
por: Van Campenhout, Raf, et al.
Publicado: (2021)

Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation
por: Van Campenhout, Raf, et al.
Publicado: (2019)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Nanobodies for the Early Detection of Ovarian Cancer
por: Tran, Lan-Huong, et al.
Publicado: (2022)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

Development and Characterization of Nanobodies Targeting the Kupffer Cell
por: Zheng, Fang, et al.
Publicado: (2021)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

The Therapeutic Potential of Nanobodies
por: Jovčevska, Ivana, et al.
Publicado: (2019)

Effects of acute and chronic disease on cell junctions in mouse liver
por: Van Campenhout, Raf, et al.
Publicado: (2023)

A guide to: generation and design of nanobodies
por: Muyldermans, Serge
Publicado: (2020)

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies
por: Zheng, Fang, et al.
Publicado: (2016)

Direct Immobilization of Engineered Nanobodies on Gold Sensors
por: Simões, Bárbara, et al.
Publicado: (2021)

Application of Single-Domain Antibodies (“Nanobodies”) to Laboratory Diagnosis
por: Pillay, Tahir S., et al.
Publicado: (2021)

Nanobodies and recombinant binders in cell biology
por: Helma, Jonas, et al.
Publicado: (2015)

Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha
por: De Vlaminck, Karen, et al.
Publicado: (2021)

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
por: Hu, Yaozhong, et al.
Publicado: (2017)

Connexin-Based Channel Activity Is Not Specifically Altered by Hepatocarcinogenic Chemicals
por: Leroy, Kaat, et al.
Publicado: (2021)

Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment
por: Sadeghnezhad, Golnaz, et al.
Publicado: (2019)

Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers
por: Arezumand, Roghaye, et al.
Publicado: (2017)

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery
por: Debie, Pieterjan, et al.
Publicado: (2019)

The structural basis of nanobody unfolding reversibility and thermoresistance
por: Kunz, Patrick, et al.
Publicado: (2018)

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells
por: Balhuizen, Alexander, et al.
Publicado: (2017)

Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies
por: Caljon, Guy, et al.
Publicado: (2012)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
por: Ruiz-López, Eduardo, et al.
Publicado: (2022)

Correction: Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies
por: Caljon, Guy, et al.
Publicado: (2012)

Science as a human endeavor
por: Kneller, George F
Publicado: (1978)

Integrative endeavor for renaissance in Ayurveda
por: Raut, Ashwinikumar A.
Publicado: (2011)

Hematophagous Endeavors, Fact and Fancy
por: Breedlove, Byron, et al.
Publicado: (2017)

Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function
por: Kazemi-Lomedasht, Fatemeh, et al.
Publicado: (2018)

High Affinity Nanobodies against the Trypanosome brucei VSG Are Potent Trypanolytic Agents that Block Endocytosis
por: Stijlemans, Benoît, et al.
Publicado: (2011)

Exploiting sequence and stability information for directing nanobody stability engineering
por: Kunz, Patrick, et al.
Publicado: (2017)

Pannexin1 channels in the liver: an open enemy
por: Van Campenhout, Raf, et al.
Publicado: (2023)

Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells
por: De Groof, Timo W. M., et al.
Publicado: (2019)

Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies
por: De Groof, Timo W. M., et al.
Publicado: (2021)

Canonical and Non-Canonical Roles of Connexin43 in Cardioprotection
por: Rusiecka, Olga M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uotv0mjmf9fbm5k8tj46umg4di